Speaker illustration

Doctor Grigor Abelian

(United States of America)

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Event: ESC Congress 2022

Topic: Anticoagulants

Session: Challenges and advances in antithrombotic therapy

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb